We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+9.61%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$43.5B
AUM Growth
+$8.16B
(+23%)
Cap. Flow
+$4.5B
Cap. Flow
% of AUM
10.34%
Top 10 Holdings %
Top 10 Hldgs %
11.55%
Holding
3,819
New
249
Increased
1,063
Reduced
1,013
Closed
119
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AT&T
T
|
+$424M |
| 2 |
Kenvue
KVUE
|
+$415M |
| 3 |
Cummins
CMI
|
+$374M |
| 4 |
Bunge Global
BG
|
+$310M |
| 5 |
Newell Brands
NWL
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$423M |
| 2 |
Qualcomm
QCOM
|
+$413M |
| 3 |
D.R. Horton
DHI
|
+$401M |
| 4 |
Booking.com
BKNG
|
+$397M |
| 5 |
Phillips 66
PSX
|
+$389M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.42% |
| 2 | Energy | 16.95% |
| 3 | Industrials | 12.39% |
| 4 | Healthcare | 10.91% |
| 5 | Technology | 10.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Beam Therapeutics
BEAM
$2.7B
| $37.5K | ﹤0.01% |
+1,134
| New | +$35.3K |
|
1302
Novavax
NVAX
$1.21B
| $37.4K | ﹤0.01% |
+7,828
| New | +$36.3K |
|
1303
Celldex Therapeutics
CLDX
$2.79B
| $37.4K | ﹤0.01% |
+890
| New | +$36.5K |
|
1304
Protolabs
PRLB
$1.78B
| $37.3K | ﹤0.01% |
1,044
| – | – |
|
1305
BioCryst Pharmaceuticals
BCRX
$2.48B
| $37.1K | ﹤0.01% |
+7,306
| New | +$41.1K |
|
1306
Keros Therapeutics
KROS
$199M
| $37.1K | ﹤0.01% |
+560
| New | +$33.2K |
|
1307
Geron
GERN
$930M
| $37K | ﹤0.01% |
+11,223
| New | +$25.1K |
|
1308
CRISPR Therapeutics
CRSP
$4.68B
| $36.7K | ﹤0.01% |
+538
| New | +$38.5K |
|
1309
Cohu
COHU
$2B
| $36.4K | ﹤0.01% |
1,093
-749,946
| -100% | -$24.4M |
|
|
MORF
1310
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $36.3K | ﹤0.01% |
+1,030
| New | +$34.5K |
|
1311
Progress Software
PRGS
$1.66B
| $36.2K | ﹤0.01% |
679
+306
| +82% | +$16.8K |
|
1312
Energizer
ENR
$1.5B
| $36.2K | ﹤0.01% |
1,228
+415
| +51% | +$12.5K |
|
|
CPRX
1313
DELISTED
Catalyst Pharmaceutical
CPRX
| $36.1K | ﹤0.01% |
+2,265
| New | +$34.1K |
|
1314
Ardelyx
ARDX
$1.25B
| $35.8K | ﹤0.01% |
+4,909
| New | +$42K |
|
1315
Vera Therapeutics
VERA
$2.39B
| $34.9K | ﹤0.01% |
+810
| New | +$28.9K |
|
1316
Prothena Corp
PRTA
$448M
| $34.9K | ﹤0.01% |
+1,410
| New | +$41.9K |
|
1317
Calix
CALX
$2.34B
| $34.8K | ﹤0.01% |
1,050
-8,041
| -88% | -$300K |
|
1318
Amphastar Pharmaceuticals
AMPH
$888M
| $34.8K | ﹤0.01% |
792
-178
| -18% | -$9.19K |
|
1319
Dine Brands
DIN
$458M
| $34.5K | ﹤0.01% |
+743
| New | +$34.5K |
|
|
AKRO
1320
DELISTED
Akero Therapeutics
AKRO
| $34.5K | ﹤0.01% |
+1,365
| New | +$32.8K |
|
|
SAGE
1321
DELISTED
Sage Therapeutics
SAGE
| $34.2K | ﹤0.01% |
+1,826
| New | +$42.1K |
|
1322
Teladoc Health
TDOC
$1.69B
| $33.8K | ﹤0.01% |
2,240
+171
| +8% | +$3.1K |
|
1323
Ambarella
AMBA
$3.03B
| $33.7K | ﹤0.01% |
664
+476
| +253% | +$26K |
|
1324
Biomea Fusion
BMEA
$90.4M
| $33.7K | ﹤0.01% |
+2,254
| New | +$37.1K |
|
1325
Acadia Pharmaceuticals
ACAD
$4.45B
| $33.7K | ﹤0.01% |
+1,822
| New | +$45.1K |
|
Similar funds
SAM
Pacer Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, Pacer Advisors held 3,819 positions worth $43.5B, up 23% from $35.3B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Pacer Advisors deployed $4.5B of net new capital in Q1 2024, opening 249 new positions and adding to 1,063 existing holdings. Its largest new stake was Hanesbrands: 32,772,533 shares worth $190M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 19% a quarter earlier, followed by Energy and Industrials.
On the sell side, the largest reduction was AbbVie, an estimated $423M trimmed.
- Pacer Advisors's largest Q1 2024 buy was Hanesbrands: 32,772,533 shares worth $190M.
- Pacer Advisors added most to AT&T in Q1 2024, an estimated $424M increase.
- Pacer Advisors's biggest Q1 2024 reduction was AbbVie, cutting an estimated $423M.
- Pacer Advisors fully exited Tri Pointe Homes in Q1 2024, selling an estimated $139M.
- Pacer Advisors's ten largest holdings make up 12% of its $43.5B portfolio in Q1 2024.
- Pacer Advisors opened 249 new positions and closed 119 in Q1 2024.
- Pacer Advisors's portfolio value rose 23% quarter-over-quarter to $43.5B.
Based on Pacer Advisors's 13F filing for Q1 2024, filed 10 May 2024.